Shouyao Holdings (Beijing) Co. LTD
Quick facts
Phase 3 pipeline
- Crizotinib Capsules · Oncology
Crizotinib is a tyrosine kinase inhibitor that blocks ALK (anaplastic lymphoma kinase) and ROS1 signaling to inhibit cancer cell growth. - SY-3505 Capsules · Diabetes
SY-3505 Capsules is a small molecule that targets the SGLT2 receptor. - SY-5007 · Diabetes
SY-5007 is a small molecule that targets the SGLT2 receptor.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Shouyao Holdings (Beijing) Co. LTD portfolio CI brief
- Shouyao Holdings (Beijing) Co. LTD pipeline updates RSS
Frequently asked questions about Shouyao Holdings (Beijing) Co. LTD
What is Shouyao Holdings (Beijing) Co. LTD's pipeline?
Shouyao Holdings (Beijing) Co. LTD has 3 drugs in Phase 3, 1 in Phase 2, 6 in Phase 1. Late-stage candidates include Crizotinib Capsules, SY-3505 Capsules, SY-5007.
Related
- Sector hub: All tracked pharma companies